Listed

Grace Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2021

Filed with the SEC on Nov 10, 2021 and accepted by EDGAR at Nov 10, 2021, 07:01 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2021-07-01 to 2021-09-30$585.0kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2021-04-01 to 2021-09-30$1.1mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-07-01 to 2021-09-30−$3.6mus-gaap:OperatingIncomeLoss
Operating income6 months2021-04-01 to 2021-09-30−$6.7mus-gaap:OperatingIncomeLoss
Net income3 months2021-07-01 to 2021-09-30$981.0kus-gaap:NetIncomeLoss
Net income6 months2021-04-01 to 2021-09-30−$2.1mus-gaap:NetIncomeLoss
Operating cash flow3 months2021-07-01 to 2021-09-30−$6.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Operating cash flow6 months2021-04-01 to 2021-09-30−$9.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2021-09-30$36.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-09-30$54.5mus-gaap:AssetsCurrent
Total assetsAt period end2021-09-30$119.8mus-gaap:Assets
Current liabilitiesAt period end2021-09-30$4.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-09-30$5.6mus-gaap:Liabilities
Shareholders' equityAt period end2021-09-30$114.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001171843-21-007766. Last ingested by Listed: Nov 14, 2026, 23:10 ET. Listed shows no prices and gives no investment advice.